Real-life incidence of thrombotic events in leukemia patients treated with ponatinib

E. Dan Nichols; Elias Jabbour; Nadya Jammal; Serena Chew; Jeffrey Bryan; Ghayas Issa; Guillermo Garcia-Manero; Koji Sasaki; Adam DiPippo; Hagop Kantarjian

doi:10.1002/ajh.26645

Real-life incidence of thrombotic events in leukemia patients treated with ponatinib

E. Dan Nichols, Elias Jabbour, Nadya Jammal, Serena Chew, Jeffrey Bryan, Ghayas Issa, Guillermo Garcia-Manero, Koji Sasaki, Adam DiPippo, Hagop Kantarjian

Research output: Contribution to journal › Letter › peer-review

3 Scopus citations

Original language	English (US)
Pages (from-to)	E350-E352
Journal	American journal of hematology
Volume	97
Issue number	9
DOIs	https://doi.org/10.1002/ajh.26645
State	Published - Sep 2022
Externally published	Yes

ASJC Scopus subject areas

Hematology

Access to Document

10.1002/ajh.26645

Cite this

@article{9726bea2476f4880b085fb22e41a2aa8,

title = "Real-life incidence of thrombotic events in leukemia patients treated with ponatinib",

author = "Nichols, {E. Dan} and Elias Jabbour and Nadya Jammal and Serena Chew and Jeffrey Bryan and Ghayas Issa and Guillermo Garcia-Manero and Koji Sasaki and Adam DiPippo and Hagop Kantarjian",

note = "Funding Information: Drs Nichols, Jammal, Chew, Bryan, Garcia‐Manero, and DiPippo have no disclosures to report. Dr Kantarjian has received research grants from AbbVie, Amgen, Ascentage, BMS, Daiichi‐Sankyo, Immunogen, Jazz, Novartis, and Pfizer; and honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, AstraZeneca, Ipsen Biopharmaceuticals, KAHR Medical Ltd, NOVA Research, Novartis, Pfizer, Precision BioSciences, and Taiho Pharma Canada. Dr Jabbour has received research grants from Amgen, AbbVie, Spectrum, BMS, Takeda, Pfizer, Adaptive, and Genentech. Dr Sasaki is a member of Pfizer's and Daiichi‐Sankyo's Board of Directors or advisory committees and has received research grants from and is a consultant for Novartis. Dr Issa has received research grants from Celgene, Kura Oncology, Syndax, and Novartis and has received consultancy fees from Novartis and Kura Oncology. ",

year = "2022",

month = sep,

doi = "10.1002/ajh.26645",

language = "English (US)",

volume = "97",

pages = "E350--E352",

journal = "American journal of hematology",

issn = "0361-8609",

publisher = "Wiley-Liss Inc.",

number = "9",

}

TY - JOUR

T1 - Real-life incidence of thrombotic events in leukemia patients treated with ponatinib

AU - Nichols, E. Dan

AU - Jabbour, Elias

AU - Jammal, Nadya

AU - Chew, Serena

AU - Bryan, Jeffrey

AU - Issa, Ghayas

AU - Garcia-Manero, Guillermo

AU - Sasaki, Koji

AU - DiPippo, Adam

AU - Kantarjian, Hagop

N1 - Funding Information: Drs Nichols, Jammal, Chew, Bryan, Garcia‐Manero, and DiPippo have no disclosures to report. Dr Kantarjian has received research grants from AbbVie, Amgen, Ascentage, BMS, Daiichi‐Sankyo, Immunogen, Jazz, Novartis, and Pfizer; and honoraria from AbbVie, Amgen, Aptitude Health, Ascentage, Astellas Health, AstraZeneca, Ipsen Biopharmaceuticals, KAHR Medical Ltd, NOVA Research, Novartis, Pfizer, Precision BioSciences, and Taiho Pharma Canada. Dr Jabbour has received research grants from Amgen, AbbVie, Spectrum, BMS, Takeda, Pfizer, Adaptive, and Genentech. Dr Sasaki is a member of Pfizer's and Daiichi‐Sankyo's Board of Directors or advisory committees and has received research grants from and is a consultant for Novartis. Dr Issa has received research grants from Celgene, Kura Oncology, Syndax, and Novartis and has received consultancy fees from Novartis and Kura Oncology.

PY - 2022/9

Y1 - 2022/9

UR - http://www.scopus.com/inward/record.url?scp=85133771167&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85133771167&partnerID=8YFLogxK

U2 - 10.1002/ajh.26645

DO - 10.1002/ajh.26645

M3 - Letter

C2 - 35759571

AN - SCOPUS:85133771167

SN - 0361-8609

VL - 97

SP - E350-E352

JO - American journal of hematology

JF - American journal of hematology

IS - 9

ER -

Real-life incidence of thrombotic events in leukemia patients treated with ponatinib

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this